Clinical Trial Update: Safety Study of Intranasal Oxytocin in Frontotemporal Dementia [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating intranasal oxytocin in individuals with Frontotemporal dementia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia

Drugs mentioned

• intranasal oxytocin (oxytocin)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Frontotemporal Dementia | Phase 1 | Status: COMPLETED